Please check your internet connection and try again.
# Flupentixol and Melitracen
## Overview
Flupentixol is a thioxanthene antipsychotic with low-dose antidepressant properties. Melitracen is a tricyclic antidepressant (TCA). The combination is used to target both psychogenic anxiety and depression through a dual mechanism of action.
## Primary Indications
Treatment of psychogenic depression, depressive neuroses, masked depression, and psychosomatic affections accompanied by anxiety and apathy.
## Adult Dosing
* **Initial Dose:** 1 tablet (0.5 mg flupentixol / 10 mg melitracen) twice daily (morning and noon).
* **Maintenance Dose:** 1 tablet daily (morning).
* **Maximum Dose:** 4 tablets daily.
* *Note:* Doses should be taken at least 4 hours apart. Avoid late afternoon or evening dosing to prevent insomnia due to the activating nature of the components.
## Pediatric Dosing
**Not established.** Safety and efficacy in children and adolescents under 18 years have not been adequately studied. Use is generally not recommended in this population.
## Dose Adjustments
* **Elderly:** Start with 1 tablet in the morning. Use with extreme caution due to increased risk of anticholinergic effects and orthostatic hypotension.
* **Hepatic/Renal Impairment:** No specific guidelines; use with caution. Reduced dosage may be necessary due to potential accumulation.
## Contraindications
* Hypersensitivity to any component.
* Recent myocardial infarction.
* Conduction defects (heart block).
* Acute alcohol, barbiturate, or opioid intoxication.
* Blood dyscrasias.
* Pheochromocytoma.
* Closed-angle glaucoma, urinary retention, or uncontrolled epilepsy.
## Adverse Effects
* **Common:** Dry mouth, insomnia, restlessness, dizziness, tremors.
* **Serious:** Extrapyramidal symptoms (at higher doses), cardiac arrhythmias (QT prolongation), agranulocytosis (rare), paralytic ileus, or suicide ideation (common with antidepressant initiation).
## Key Drug Interactions
* **MAO Inhibitors:** Risk of hypertensive crisis. Must be separated by at least 14 days.
* **CNS Depressants:** Enhances effects of alcohol, barbiturates, and opiates.
* **Antihypertensives:** Potential for additive hypotension.
* **QT Prolonging Agents:** Increased risk of ventricular arrhythmias.
## Monitoring
* **Cardiac:** Baseline and periodic ECG monitoring for patients with cardiac history or risk factors for QT prolongation.
* **Psychiatric:** Monitor closely for worsening depression or emergence of suicidal ideation, especially during the first few weeks of therapy.
* **Clinical:** Monitor for anticholinergic side effects (e.g., urinary retention, constipation).
## Clinical Pearls
* **Activation:** The drug is intentionally stimulating; therefore, avoid doses after 3:00 PM to mitigate insomnia.
* **TCA Properties:** Due to the melitracen component, this drug shares the typical side effect profile of older TCAs (anticholinergic, sedative).
* **Efficacy:** If there is no response after one week of treatment at the maximum tolerated dose, the therapy should be reevaluated.
* **Availability:** This combination is not approved by the FDA (USA). Ensure availability is confirmed via local drug regulatory authorities.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice protocols vary by region. Always consult current, local prescribing information (package insert) and clinical guidelines before prescribing or administering medication.
